Greenwich LifeSciences Expands FLAMINGO-01 Breast Cancer Trial To Ireland

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company advancing GLSI-100, an immunotherapy designed to prevent breast cancer recurrence, announced the expansion of its Phase III FLAMINGO-01 trial to Ireland.

The company has received formal approval from European regulators to include Ireland in the study, which already spans Spain, France, Germany, Italy, Poland, Romania, and the United States. 

CEO Snehal Patel said, "We have visited St. Vincent's multiple times over the past few years, once to present GP2 and FLAMINGO-01 at their conference and most recently to train the study team. We have also been approached by Irish breast cancer patients who wish to participate in FLAMINGO -01 and who can now be considered for enrollment through the Dublin site."

According to the European Cancer Information System, Ireland recorded 3,723 new cases of breast cancer in 2022, making it the most common cancer among women and accounting for roughly 30% of female cancers. Breast cancer also remains the second leading cause of cancer-related deaths among women in the country, with 883 deaths reported in 2022.

Greenwich LifeSciences is partnering with Dr. Janice Walshe, who will serve as the national principal investigator for FLAMINGO-01 in Ireland. Based at St Vincent's University Hospital in Dublin, Dr. Walshe is an active member of Cancer Trials Ireland and has served as principal investigator in numerous international breast cancer trials. Her research contributions have been presented globally and published in leading peer-reviewed journals.